EUVIMEDEUVIMED entdecken
Open Access

Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy‐Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization

Tomomasa Matsuo iD, Yu Ozawa iD, Atsunori Yorozu, Seiya Hattori, Yuta Kaneko, Ken Nakamura, Yasuto Yagi, Toru Nishiyama, Shiro Saito, Tetsuo Monma

International Journal of Urology · 2026-07 · 33 (7)

DOI: 10.1111/iju.70574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 14.07.2026. Verfasst von Tomomasa Matsuo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the prognostic impact of Grade Group (GG) 5 following permanent seed implantation brachytherapy‐based trimodality therapy.

Methods

We retrospectively analyzed 352 men with National Comprehensive Cancer Network high‐risk prostate cancer treated with trimodality therapy (low‐dose‐rate brachytherapy, external beam radiation therapy, and androgen deprivation therapy [ADT]) between 2003 and 2019. Staging included computed tomography, magnetic resonance imaging, and bone scintigraphy. Endpoints were biochemical recurrence (BCR; Phoenix definition), overall survival (OS), and cancer‐specific survival (CSS). Survival outcomes were assessed using the Kaplan–Meier and log‐rank tests. Multivariable Cox proportional hazards models, adjusting for prostate‐specific antigen, clinical stage, duration of ADT, and biologically effective dose (BED), evaluated the association between GG5 and BCR. Clinical recurrence patterns post‐BCR were assessed.

Results

Median follow‐up was 8.2 years (interquartile range [IQR] 5.4–10.0); median BED was 214 Gy (IQR 207–222). Among three study groups (GG1–3, GG4, and GG5), GG5 ( n = 106) exhibited significantly lower BCR‐free survival ( p = 0.002) and CSS ( p = 0.045), while OS was comparable ( p = 0.3). GG5 remained an independent risk factor for BCR after the adjustment (vs. GG1–4, hazard ratio 2.78, 95% confidence interval 1.60–4.82, p < 0.001). GG5 recurrences predominantly involved the pelvic nodes or bone, whereas local and visceral metastases were infrequent.

Conclusions

This study demonstrated that GG5 is an independent predictor of BCR and cancer‐specific mortality after trimodality therapy. Despite high BED, the propensity for nodal and bone metastases suggests the need for intensified staging and systemic therapy to optimize outcomes for GG5 disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBrachytherapyNeoplasm Recurrence, LocalHumansMaleRetrospective StudiesNeoplasm StagingPrognosisAgedAndrogen AntagonistsNeoplasm GradingMiddle AgedProstateCombined Modality TherapyProstate-Specific AntigenBone Neoplasms

Stichwörter der Autor:innen

brachytherapycombined modality therapyprostatic neoplasmstreatment prognosistumor grading

Substanzen

Androgen AntagonistsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Department of Radiation Oncology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Department of Urology, Prostate Cancer Center, Ofuna Chuo Hospital, Kanagawa, Japan.

ORCID-Profile: Tomomasa Matsuo, Yu Ozawa

Zitieren

APA

Matsuo, T., Ozawa, Y., Yorozu, A., Hattori, S., Kaneko, Y., Nakamura, K., Yagi, Y., Nishiyama, T., Saito, S., & Monma, T. (2026). Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy‐Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization. International Journal of Urology, 33(7). https://doi.org/10.1111/iju.70574

Vancouver

Matsuo T, Ozawa Y, Yorozu A, Hattori S, Kaneko Y, Nakamura K, et al. Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy‐Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization. International Journal of Urology. 2026;33(7). doi:10.1111/iju.70574

BibTeX
@article{Matsuo2026,
  author = {Matsuo, Tomomasa and Ozawa, Yu and Yorozu, Atsunori and Hattori, Seiya and Kaneko, Yuta and Nakamura, Ken and Yagi, Yasuto and Nishiyama, Toru and Saito, Shiro and Monma, Tetsuo},
  title = {Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy‐Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1111/iju.70574}
}
Kostenlos starten →